PRNewsWire
15 Jul 2026, 11:45 UTC · 16w ago
Verdict
Headline takes no side. We score INTS +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 73% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Intensity Therapeutics has restarted patient dosing in its Phase 2 INVINCIBLE-4 study for triple-negative breast cancer (TNBC).
So whatResuming a clinical trial after a pause is a positive regulatory and operational milestone that keeps the lead candidate's development timeline alive.
More positive than 76% of claims this week
The INVINCIBLE-4 study was previously paused to evaluate skin irritation issues observed in some patients.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More negative than 78% of claims this week
Early data from 14 patients showed a favorable trend toward fewer grade 3 or higher adverse events for those receiving INT230-6 compared to standard-of-care alone.
More positive than 61% of claims this week
The company modified the trial protocol to use a lower drug-to-tumor volume ratio and a single injection of INT230-6 to address safety concerns.
So whatProtocol amendments are common in Phase 2; while it shows a reaction to adverse events, it demonstrates a proactive path to continuing the trial.
More positive than 39% of claims this week
Which stocks this story touches
More positive than 73% of ticker scores this week
The company has restarted a Phase 2 clinical trial for its lead candidate and reported a favorable trend in early safety data.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
8h ago
−41.7%
Price is moving against the score
$2.84 vs $4.87 close before publication (Jul 14) · not market-adjusted
INTS chart →
